Eleven lymphoid phenotypic markers in HIV infection: selective changes induced by zidovudine treatment.
HIV infection induces substantial changes in the expression of many lymphocyte phenotypic markers as well as depletion of CD4 lymphocyte numbers. A comprehensive study was undertaken to determine whether seven lymphocyte phenotypic changes associated with HIV infection (increased CD38, HLA-DR, CD57, and CD71 and decreased CD11b, CD45RA, and leu-8) are altered by zidovudine (ZDV) administration. Levels of the four major lymphoid subsets (CD4, CD8, B, and NK cells) and changes in the serum activation markers neopterin and beta 2-microglobulin (beta 2M) were also measured. Elevated pretreatment expression of CD38 and CD71 was reduced significantly toward normal at 2 weeks by ZDV; however, CD38 and CD71 returned to pretreatment levels at different rates. The kinetics of CD38 reduction and the return to pretreatment levels were similar to those of serum neopterin and beta 2M. HLA-DR decreased in many but not all subjects. CD4 lymphocytes showed a transient increase, most evident at 8 weeks of treatment. Lymphoid phenotypes that did not show significant changes after ZDV therapy included CD57, CD11b, CD45RA, and leu-8 markers as well as CD8 T cells, CD20 B cells, and CD56 NK cells. The fact that some lymphocyte phenotypic markers change toward normal with ZDV treatment and others do not indicates that complex processes underlie immune perturbations of HIV infection. Several phenotypic markers (CD38, CD71, and HLA-DR) that are susceptible to short-term effects of ZDV (but with changes that differ from CD4 T cell changes) are surrogate marker candidates for evaluation in anti-HIV treatment.
Bass
H Z
HZ
Center for Interdisciplinary Research in Immunology and Disease (CIRID), UCLA School of Medicine 90024-1747.
Hardy
W D
WD
Mitsuyasu
R T
RT
Wang
Y X
YX
Cumberland
W
W
Fahey
J L
JL
D015415:Biomarkers; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007700:Kinetics; D010641:Phenotype; D016176:T-Lymphocyte Subsets / Q000187:drug effects*; D015215:Zidovudine / Q000627:therapeutic use*
D015415:Biomarkers; D015215:Zidovudine